Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29874931 | 0.83 | ECE2 (0.59) | ECE2CA2NPC1RAB9AHPGD | |
| SCHEMBL2496318 | 0.83 | ECE2 (0.59) | ECE2CA2NPC1RAB9AHPGD | |
| Potassium Ion SCHEMBL22587793 | 0.81 | ECE2 (0.58) | ECE2NPC1RAB9AHPGDANO1 | |
| SCHEMBL29306046 | 0.81 | ECE2 (0.58) | ECE2NPC1RAB9AHPGDNFKB1 | |
| SCHEMBL16053866 | 0.81 | ECE2 (0.50) | ECE2NPC1RAB9AHPGDSTAT1 | |
| SCHEMBL2495821 | 0.81 | ECE2 (0.54) | ECE2NPC1RAB9AHPGDANO1 | |
| SCHEMBL5340760 | 0.80 | HDAC3 (0.60) | NPC1RAB9AANO1KDM4EALDH1A1 | |
| SCHEMBL5340727 | 0.80 | RAB9A (0.59) | CA2NPC1RAB9AHPGDNFKB1 | |
| SCHEMBL12985473 | 0.80 | MAOB (0.47) | ECE2CA2NPC1RAB9AHPGD | |
| SCHEMBL31269838 | 0.80 | HDAC3 (0.60) | NPC1RAB9AANO1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105102459-A | Antiviral indolo[2,3-b]quinoxaline | VIRONOVA AB | 2015-11-25 | — | — | CN | claimed |
| CN-1976934-B | Alkyl substituted indoloquinoxalines | OXYPHARMA AB | 2013-05-29 | — | — | CN | claimed |
| CN-1976934-A | Alkyl substituted indoloquinoxalines | OXYPHARMA AB (SE) | 2007-06-06 | — | — | CN | claimed |
| EP-2970292-A1 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE | Vironova Herpes AB (SE) | 2016-01-20 | — | — | EP | disclosed |
| CN-105102459-A | Antiviral indolo[2,3-b]quinoxaline | VIRONOVA AB | 2015-11-25 | — | — | CN | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2014140321-A1 | ANTIVIRAL INDOLO[2,3-B]QUINOXALINE | VIRONOVA AB (SE) | 2014-09-18 | — | — | WO | disclosed |
| CN-1976934-B | Alkyl substituted indoloquinoxalines | OXYPHARMA AB | 2013-05-29 | — | — | CN | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| CN-1976934-A | Alkyl substituted indoloquinoxalines | OXYPHARMA AB (SE) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | ECE2 2157/4885CA2 3769/4885NPC1 3907/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | ECE2 2157/4885CA2 3769/4885NPC1 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.